Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation for securities fraud, following a significant drop in stock price after the company reported disappointing financial results for Q2 2025 [1][3]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Fluor securities between February 18, 2025, and July 31, 2025, with a deadline of November 14, 2025, to file a lead plaintiff motion [1][2]. - The lawsuit alleges that Fluor made materially false and misleading statements regarding its business operations and financial outlook during the class period [4]. Group 2: Financial Performance - On August 1, 2025, Fluor reported Q2 2025 financial results that missed consensus estimates, attributing the shortfall to rising costs from subcontractor design errors, price increases, and scheduling delays, along with reduced capital spending from clients [3]. - Following the announcement, Fluor's stock price fell by $15.35, or 27%, closing at $41.42 per share, which negatively impacted investors [3]. Group 3: Allegations Against Defendants - The complaint claims that the defendants failed to disclose significant adverse facts, including rising costs in key projects and the negative impact of economic uncertainty on the company's financial results [4]. - It is alleged that Fluor's financial guidance for FY 2025 was unreliable, and the effectiveness of its risk mitigation strategies was overstated [4].

Core Viewpoint - A securities class action lawsuit has been filed against Fluor Corporation for alleged misleading statements and undisclosed costs related to specific projects, impacting the company's financial guidance and risk assessment [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Fluor securities between February 18, 2025, and July 31, 2025, with a lead plaintiff deadline set for November 14, 2025 [1]. - Allegations include that Fluor failed to disclose rising costs associated with the Gordie Howe International Bridge and Texas highway projects due to subcontractor errors, price increases, and scheduling delays [2]. - The complaint asserts that these issues, along with reduced customer capital spending and economic uncertainty, negatively impacted Fluor's business and financial results [2]. Group 2: Lead Plaintiff Process - Investors may seek to be appointed as lead plaintiffs by the November 14, 2025 deadline, or they can choose to remain absent class members [3]. - The lead plaintiff represents the interests of all class members and selects legal counsel for the case [3]. Group 3: Law Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected]. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior ...

SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of KinderCare Learning Companies, Inc. (NYSE: KLC) common stock in or traceable to KinderCare’s October 2024 initial public offering (the “IPO”), have until Monday, October 13, 2025 to seek appointment as lead plaintiff of the KinderCare class action lawsuit. Captioned Gollapalli v. KinderCare Learning Companies, Inc., No. 25-cv-01424, and pending in the District of Oregon, the KinderCare class action la ...

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Snap Inc. (“Snap” or the “Company”) (NYSE: SNAP) between April 29, 2025 and August 5, 2025, inclusive. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Snap Inc. (NYSE: SNAP)?Did you purchase your shares between April 29, 2025 and August 5, 2025, inclusive?Did y ...

Group 1 - The Schall Law Firm has initiated a class action lawsuit against Unicycive Therapeutics, Inc. for violations of the Securities Exchange Act of 1934 [1][4] - The class period for the lawsuit is defined as between March 29, 2024, and June 27, 2025, during which investors are encouraged to participate if they suffered losses [2] - The complaint alleges that Unicycive made false and misleading statements regarding its FDA manufacturing compliance and the likelihood of FDA approval for its treatment OLC [4] Group 2 - Investors are advised to contact the Schall Law Firm to discuss their rights and potential participation in the lawsuit [3] - The class has not yet been certified, meaning that until certification occurs, investors are not represented by an attorney [3] - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation [5]

Core Points - Rosen Law Firm is reminding purchasers of Lockheed Martin Corporation securities about a class action lawsuit with a lead plaintiff deadline of September 26, 2025 [1][3] - Investors who purchased Lockheed Martin securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Company Details - The lawsuit alleges that Lockheed Martin made false and misleading statements regarding its internal controls, risk management, and contract commitments, which led to significant losses for investors [5] - Specific claims include the lack of effective internal controls, inaccurate program reviews, and overstated delivery capabilities, resulting in materially misleading statements about the company's business and prospects [5] Legal Process - To join the class action, investors can submit a form or contact the law firm directly for more information [3][6] - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7]

Core Viewpoint - A class action lawsuit has been filed against Quanex Building Products Corporation and certain officers for alleged violations of federal securities laws during the Class Period from December 12, 2024, to September 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased or acquired Quanex securities during the specified Class Period [2]. - The complaint alleges that the defendants made materially false and misleading statements and failed to disclose adverse facts about the Company's business and operations [3]. - Specific allegations include underinvestment in tooling and equipment maintenance at the Tyman Mexico facility, leading to degraded conditions and potential significant costs that could delay expected benefits from the Tyman integration [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Quanex have until November 18, 2025, to request to be appointed as lead plaintiff in the case [4]. - A copy of the complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm represents investors on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, specifically related to undisclosed challenges in product adoption and subsequent revenue forecast cuts [1][2][4]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Issues - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased RxSight securities [2]. - The case is currently pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596 [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a significant decline in stock price following the announcement of a reduced revenue forecast on April 3, 2025, with shares dropping approximately 38% from $26.12 to $16.21 [5]. - A further revenue forecast cut on July 8, 2025, led to another 38% decline in stock price, from $12.79 to $7.95, attributed to slower LAL utilization and adoption challenges [6].

Group 1 - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of V.F. Corporation securities between October 30, 2023, and May 20, 2025 [1] - Investors who purchased V.F. Corporation securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A lead plaintiff must move the Court by November 12, 2025, to represent other class members in the litigation [3] Group 2 - The lawsuit alleges that V.F. Corporation's defendants disseminated materially false and misleading statements regarding the company's turnaround plans, particularly concerning the Vans brand [5] - The lawsuit claims that defendants concealed the need for additional significant reset actions to return the Vans brand to growth, which would negatively impact revenue growth [5]